Ace Report Cover
Biochemical and clinical outcomes between IV vs. topical tranexamic acid for blood loss in TKA
Download
Reprints
Cite This
+ Favorites
Download
Reprints
Cite This
+ Favorites
AceReport Image
ARTHROPLASTY
Biochemical and clinical outcomes between IV vs. topical tranexamic acid for blood loss in TKA
J Bone Joint Surg Am. 2019 Sep 20.

66 patients were randomized to receive topical tranexamic acid (TXA) or intravenous (IV) TXA for the reduction of blood loss in total knee arthroplasty (TKA). The primary outcome of interest was the systemic and wound levels of plasma-anti-plasmin (PAP). Additional outcomes of interest included systemic and wound levels of prothrombin fragment 1.2 (PF1.2), interleukin (IL)-6 and TXA, total blood loss, drainage volume, time to discharge from physical therapy, length of stay, hemoglobin levels and hematocrit levels. Results revealed significantly lower levels of systemic PAP at 4 hours post-tourniquet release, higher systemic and wound TXA levels, and shorter length of stay in the intravenous group compared to the topical group. Hemoglobin levels on post-operative day 1 and 2 as well as hematocrit levels on post-operative day 2 were significantly higher in the intravenous group compared to the topical group.

Unlock the full ACE Report

You have access to {0} free articles per month.
Click below to unlock and view this {1}
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
{0} of {1} free articles

Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.

Upgrade Now
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade Account
Upgrade
Search
Close Search Window
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. Biochemical and clinical outcomes between IV vs. topical tranexamic acid for blood loss in TKA. ACE Report. 2020;10(1):24. Available from: https://myorthoevidence.com/AceReport/Report/

Copy Citation
Share this Ace Report